MiddleBrook Pharmaceuticals, Inc

What MiddleBrook Pharmaceuticals, Inc does

MiddleBrook Pharmaceuticals, Inc. is a publicly traded pharmaceutical company listed on NASDAQ under ticker MBRK, founded in 2000 and headquartered in West Lake Hills, Texas. Per the firmographic data, the company is positioned in the anti-infective product and antibiotics therapeutic category and operates with a stated headcount of 251-500 employees.

The available dataset is materially thin on operational specifics. The corporate website (middlebrookpharma.com) is currently listed for sale on the Atom domain marketplace rather than hosting an active company site, and no product portfolio, technology platform, management team, partnerships, certifications, regulatory actions, or M&A history is documented in the provided data. There are no disclosed products, pricing, distribution channels, marketing channels, or named customers, so the business model and revenue mechanics cannot be characterized from the input.

The company has raised approximately $131 million across three funding rounds between November 2007 and July 2008. Equity Group Investments led a $100 million round in July 2008, with prior rounds funded by HealthCare Ventures and Rho Ventures ($21M, February 2008) and Deerfield ($10M, November 2007). The absence of any documented post-2008 capital, product, or operational activity, combined with the dormant website, raises material uncertainty about the company's current operating status and renders most investment-relevant attributes unverifiable from the available evidence.

Name

MiddleBrook Pharmaceuticals, Inc

Website

https://middlebrookpharma.com

Company type

Private

Founded year

2000

Headcount range

251–500 employees

Short description

MiddleBrook Pharmaceuticals, Inc. is a publicly traded pharmaceutical company (NASDAQ: MBRK) offering anti-infective products and antibiotics, headquartered in West Lake Hills, Texas with 251-500 employees.

Ownership category

akta.pro rank

Product category

Anti-infective Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Anti-infective pharmaceuticals
• Antibiotic drug products
• Pharmaceutical manufacturing
• Prescription antibiotic therapy
• Infectious disease drugs

Headquarters

HQ city

West Lake Hills

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

MiddleBrook Pharmaceuticals develops, manufactures, and commercializes anti-infective pharmaceutical products, primarily antibiotics, intended for the treatment of bacterial infections. The offerings are targeted at healthcare providers and patients requiring branded antibiotic therapies for infectious diseases.

Product overview

MiddleBrookPharma.com is a premium domain name listed for sale on Atom Marketplace. It is not an existing product or service offering from an operational company; rather, it represents a domain asset potentially suitable for healthcare, biotech, telehealth, or pharmaceutical ventures. No active product portfolio, named offerings, or technology platform exists for this domain listing.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Direct peers

• Melinta Therapeutics: Anti-infectives pure-play commercializing antibiotics including Baxdela and Orbactiv. Directly comparable to MiddleBrook as a fellow antibiotics-focused company serving hospital and infectious-disease prescribers in the US.
• Paratek Pharmaceuticals: Commercial-stage anti-infective company (Nuzyra/seysara). Comparable as a focused antibiotics commercial-stage company with similar regulatory-approved portfolio positioning and stewardship constraints.
• Spero Therapeutics: Clinical-stage anti-infectives company developing antibiotics for multidrug-resistant infections. Comparable niche focus on novel-mechanism antibiotics addressing AMR-driven demand, similar regulatory and commercial pathway to an anti-infective specialist.
• Tetraphase Pharmaceuticals: Anti-infective company known for Xerava (eravacycline) — a comparable antibiotics specialist whose commercialization challenges illustrate the category economics any anti-infective specialist faces.
• Iterum Therapeutics: Anti-infective company developing oral and IV antibiotics for resistant pathogens. Directly comparable small-cap, antibiotics-focused profile targeting similar hospital/institutional prescribers.
• Nabriva Therapeutics: Anti-infectives company developing antibiotics (e.g., lefamulin/Xenleta) for community and hospital settings. Directly comparable antibiotics pure-play with similar commercial-stage execution challenges.

Others

• Achaogen: Historical anti-infective company (plazomicin/Zemdri) that filed for bankruptcy post-launch. Included as a peer primarily for relevant warning about commercial outcomes in the antibiotics category rather than as a current competitor.

Emerging players

• Cidara Therapeutics: Anti-infective company developing novel antibacterials and antivirals. Comparable as a specialist addressing infectious-disease treatment, with adjacent product-class exposure (antibacterials). Useful proxy for category economics.
• VenatoRx Pharmaceuticals: Clinical-stage anti-infective company developing novel antibiotics targeting resistant infections. Comparable focus area (anti-infectives) and AMR-driven opportunity, though earlier stage and narrower in commercialization.

Regional players

• Motif Bio: UK-listed antibiotics developer (iclaprim). Comparable antibiotics-focused profile with comparable stewardship and pricing dynamics, though geographically distinct (UK/Europe vs US anchor).

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/57718

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiddleBrook Pharmaceuticals, Inc